



(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
**25.08.2004 Bulletin 2004/35**

(51) Int Cl.7: **A61K 9/24**

(21) Application number: **03003813.7**

(22) Date of filing: **20.02.2003**

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR**  
**HU IE IT LI LU MC NL PT SE SI SK TR**  
Designated Extension States:  
**AL LT LV MK RO**

(72) Inventor: **Salini, Alberto**  
**6900 Lugano (CH)**

(74) Representative: **Minoja, Fabrizio, Dr.**  
**Bianchetti Bracco Minoja S.r.l.**  
**Via Plinio, 63**  
**20129 Milano (IT)**

(71) Applicant: **CROSS CHEM LLC**  
**San Diego CA, 92121 (US)**

(54) **chewing gum in the form of multi-layer tablets**

(57) Disclosed are tablets comprising at least one inner layer of gum base containing one or more active pharmaceutical, dietetic or nutritional ingredients and at least one outer layer comprising excipients/compression adjuvants and possibly active ingredients which are the same as or different from those present in the inner

layer.

Said tablets are obtainable by direct compression of mixtures or granulates of the various components of each layer.

**Description**

[0001] This invention relates to chewing gum in the form of multilayer tablets.

**Prior art**

[0002] Chewing gum is used with increasing frequency as a way of delivering active pharmaceutical or nutraceutical ingredients. The typical manufacturing process requires the base gum to be heated to softening temperature or melted at a temperature of approx. 80°C in suitable mixers; components such as plasticizer, sweeteners, flavouring agents and possibly other active components of the formulation are added to the molten mass. After mixing, the mass obtained is drawn into strips, cooled and cut to size.

[0003] However, although this manufacturing process can be used for thermostable products, it cannot easily be used to prepare systems that carry thermolabile substances such as most drugs and particular active substances such as probiotics.

[0004] In order to overcome these limitations, numerous chewing gum manufacturing methods have been proposed, such as those described in US 6,423,336 (23.7.2002) and WO 02/051258 (04.7.2002). Chewing gums containing dental hygiene products (patent application US 2002/0071858; 13.6.2002), breath-freshening substances (US 2002/0122843; 5.9.2002) and nutraceutical substances (EP 1254664; 06.11.2002), obtained with a compression process, were recently described. However, in all these patents the description of the manufacturing process is very vague, and nothing is said about the problems that occur during the process of compressing the gum mixtures. One of the major and sometimes insurmountable problems encountered in the process of compressing gum materials is that when the gum bases are compressed, the compacted material adheres strongly, especially to the upper and lower punches of the tablet press, causing obvious problems with the speed and quality of a large-scale production process. This phenomenon is particularly evident in view of the fact that the gum base is adhesive by nature and constitutes the largest proportion of the formulation; moreover, the compression process amplifies this behaviour of the material. These problems make the manufacturing process very difficult, and normally require a very low production speed and the use of complex tablet-press cooling systems. In any event, the adherence of the material to the punches considerably limits the formulation and the maximum amount of active component which can be carried. Moreover, the surface of the tablet is neither regular nor homogeneous. A further process of coating and/or film-coating is needed to conceal these imperfections, leading to an increase in manufacturing costs.

**Description of the invention**

[0005] It has now been found that the drawbacks of the known technique can be overcome by producing tablets comprising at least one inner layer of gum base containing one or more active pharmaceutical, dietetic or nutritional ingredients and at least one outer layer comprising excipients/compression adjuvants by direct compression.

[0006] The term "excipients/compression adjuvants" means any substance or mixture of substances able to coat the inner layer of gum base with one or more layers which promote the process of compression of the system and prevent the punches from adhering to the tablet press.

[0007] Examples of such excipients/adjuvants include lactose, starch, modified starch, microcrystalline cellulose, sorbitol, xylitol, maltitol, isomalt, maltol, mannitol, maltodextrins, cyclodextrins, saccharose, oligosaccharose, fructose, oligofructose, dextrose, talc, colloidal silicon dioxide, magnesium stearate, starch paste, methylcellulose, ethylcellulose and polyethylene glycol.

[0008] The tablets according to the invention are preferably constituted by a middle layer containing the gum base and an active substance and two outer layers constituted by said excipients/compression adjuvants.

[0009] Alternatively, the tablets can comprise two, three or more inner layers of gum base, each of which may contain active ingredients which are the same as or different from those present in the other layers, or may be constituted by a formulation with the sole function of separating layers containing incompatible active substances.

[0010] The outer layers are the only part of the formulation that comes into contact with the punches during the compression process, so all adherence problems are completely solved, and the difficulties encountered in the process of compressing gum bases only are overcome. The invention also allows continuous, high-speed manufacture using conventional tablet presses. A further advantage of the invention is that the gum base and the active substance carried by it are not heated during the manufacturing process, and are protected by the outer layers during the compression stage.

[0011] Thermolabile substances such as drugs, bioactive substances, probiotics, prebiotics, nutritional, food and confectionery substances can be carried by the process according to the invention, either alone or in association with other substances.

[0012] The outer layers can also contain an active component which is the same as or different from the one contained

in the middle layer.

**[0013]** Examples of drugs contained in one or more layers of the tablets according to the invention include analgesic, antipyretic, anaesthetic, anti-allergic, antiinflammatory, antifungal and bronchodilator drugs, antibiotics, drugs active on the cardiovascular system, decongestants, disinfectants, expectorants, mucolytics, cough suppressants, anorectics and spasmolytics, together with probiotics, prebiotics, enzymes and the like.

**[0014]** Specific examples of said drugs include acetylsalicylic acid, auranofin, bendazac, benzidamine, diclofenac, diflunisal, etodolac, fenbufen, fenoprofen calcium, flurbiprofen, ibuprofen, indometacin, ketoprofen, ketorolac trometamol, mefenamic acid, naproxen, nimesulide, paracetamol, phenylbutazone, piroxicam, sulindac and suprofen; acetylcysteine, ambroxol hydrochloride, bromexine, carbocysteine, dextromethorphan, guaifenesin, ipecacuanha, levopropoxyphene napsylate, methylcysteine, morclofone, pholcodine, potassium guaicol sulphate, sobrerol and zipeprol hydrochloride; almitrine dimesylate, amphetamine, carnitine, acetyl carnitine, ciclazindol hydrochloride, dexamphetamine sulphate, dexfenfluramine hydrochloride, amfepramone hydrochloride, doxapram hydrochloride, fenfluramine hydrochloride, benzfetamine hydrochloride, cathinone, dexfenfluramine, diethylpropion hydrochloride, orlistat, sibutramine, sildenafil, apomorphine hydrochloride, tadalafil, vardenafil, methylphenydate hydrochloride, methylamphetamine, pemoline, pentetazocine, fentermine, propylhexedrine; benzalkonium chloride, benzethonium chloride, cetrimide, cetrimonium bromide, cetylpyridinium chloride, chlorhexidine and its salts, chlorocresol, chloroxylenol, chlorophene, cresol, dequalinium chloride, domiphen bromide, hexetidine, hexylresorcinol; ketotifen fumarate, sodium nedocromil, sodium chromoglycate, tiacrilast, alprazolam, amylobarbitone, bromperidol, buspirone hydrochloride, camazepam, chlordiazepoxide, chlormethiazole, chlorpromazine, clobazam, clozapine, diazepam, droperidol, flunitrazepam, fluphenazine decanoate, haloperidol, flurazepam, lorazepam, loxapine, methaqualone, midazolam hydrochloride, nitrazepam, perphenazine, prochlorperazine, promazine, sulphuride, temazepam, zopiclone; trifluoperazine hydrochloride, tetrazepam, tiapride, dopamine hydrochloride, ephedrine hydrochloride, ethylephrine hydrochloride, fenoterol hydrobromide, ibopamine hydrochloride, hydroxyamphetamine hydrobromide, isoprenaline, metaraminol tartrate, methoxamine hydrochloride, naphazoline hydrochloride, noradrenaline hydrochloride, phenylpropanolamine hydrochloride, salbutamol, terbutaline, oxybutinin hydrochloride, propantheline bromide, naloxone hydrochloride, naltrexone hydrochloride, amoxicillin, ampicillin, azithromycin, amphotericin, bacampicillin hydrochloride, cefaclor, cefuroxime axetil, ciprofloxacin, clarithromycin, clindamycin hydrochloride, doxycycline hydrochloride, fusidic acid, minocycline, norfloxacin, rifampicin, fluconazole, itraconazole, nystatin, acyclovir, inosine pranobex, tribavirin, zidovudine, corticosteroids, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, triamcinolone, amitriptyline hydrochloride, clomipramine hydrochloride, desipramine hydrochloride, doxepin hydrochloride, fluoxetine hydrochloride, imipramine hydrochloride, mianserin hydrochloride, nortriptyline hydrochloride, trazodone hydrochloride, tryptophan; vitamins or vitaminic substances in general, essential aminoacids, enzymes, coenzymes, yeasts, probiotics, prebiotics, nutritional and diet supplements, bisacodyl, sodium carboxymethylcellulose, cascara extract, cimetidine, cisapride, dantrolene, diphenoxylate hydrochloride, docusate calcium, domperidone, famotidine, gefarnate, lactulose, loperamide, lansoprazole, mesalazine, metoclopramide hydrochloride, nizatidine, omeprazole, phenolphthalein, ranitidine, senna, sucralfate, sulfasalazine, trospium chloride, acrivastine, astemizole, brompheniramine maleate, carbinoxamine maleate, chlorpheniramine maleate, cyproheptadine hydrochloride, dimenhydrinate, diphenhydramine, doxylamine succinate, flunarizine hydrochloride, mepyramine, prometazine, terfenadine, triphenylamine, triprolidine, acipimox, bezafibrate, clofibrate, fenofibrate, gemfibrozil, lovastatin, probucol, simvastatin and statins in general, alfentanil hydrochloride, buprenorphine hydrochloride, codeine, dextropropoxyphen, methadone hydrochloride, pentazocine, xanthines such as aminophylline, caffeine, diprophylline, theophylline, disulfiram, ginkgo biloba, papain, pepsin, ubiquinolone and valerian extract.

**[0015]** These components may be contained in a single layer of the chewing gum, either alone or in association, or can be carried in a number of layers. The active component content is between 0.5% and 90% on the weight of the layer which carries said active substance, and preferably between 2 and 60%.

**[0016]** Gum bases with different characteristics and complex compositions, generally with a gum content of between 20% and 98%, and preferably between 30 and 90% by weight, can be used to make chewing gums. Plasticizers chosen from the group of polyols such as sorbitol, xylitol, maltitol, isomalt, maltol, mannitol, maltodextrins and cyclodextrins can be added in order to obtain a chewing gum with the optimum organoleptic and chewability characteristics. Said plasticizers are present in a percentage of between 0.5 and 70.0%, and preferably between 1.0 and 50.0% by weight.

**[0017]** Multi-layer chewing gum is made by compressing mixtures of powders and/or granulates; some components or mixtures of components can be previously subjected to conventional treatments such as wet or dry granulation.

**[0018]** The formulation of each layer comprises adjuvants and excipients commonly used in the pharmaceutical industry, such as lactose, starch, modified starch, microcrystalline cellulose, sorbitol, xylitol, maltitol, isomalt, maltol, mannitol, maltodextrins, cyclodextrins, saccharose, fructose, dextrose, talc, colloidal silicon dioxide, magnesium stearate, starch paste, methylcellulose, ethylcellulose, polyvinylpyrrolidone, gelatin, pectin and other known adjuvants.

**[0019]** Sweeteners such as saccharose, saccharine, sodium saccharine, aspartame, acesulfame acid and its potassium salt, cyclamic acid, calcium cyclamate, sodium cyclamate, ammonium glycyrrhizinate and other sweeteners com-

## EP 1 449 525 A1

monly used in the food and pharmaceutical industries, such as oligosaccharides, fructose, dextrose, lactose, glucose, maltitol, maltol, maltodextrins, mannitol, sorbitol and xylitol, can also be added. Said sweeteners are present in a percentage by weight of between 0.5 and 50.0%, preferably between 1.0 and 25.0%, and more preferably between 2 and 15%. The formulation can also include flavouring agents in a percentage by weight of between 0.5 and 20.0%, and preferably between 2 and 10.0%.

### Example 1

[0020] Preparation of three-layer tablets containing 100 mg of acetylcysteine in the middle layer.

1-a Preparation of mixture used for the outer layers.

[0021] Each outer layer has the following unit composition:

Xylitol (Xylisorb)	100.00 mg
Maltodextrin	100.00 mg
Talc (C. Erba)	5.00 mg
Magnesium stearate (C. Erba)	5.00 mg
Colloidal silicon dioxide (Syloid 244 - Grace)	2.00 mg
Mint flavouring (Peppermint)	5.00 mg
Total weight	217.00 mg

[0022] Xylitol + maltodextrin are mixed for 10 minutes. The remaining components are then added, and mixing continues for a further 20 minutes, to produce a homogeneous mixture.

1-b Preparation of mixture constituting the middle layer.

[0023] The inner layer has the following unit composition:

Acetylcysteine (Moehs)	100.00 mg
Gum Base (Flarer - PG Mondo TA)	500.00 mg
Talc (C. Erba)	10.00 mg
Magnesium stearate (C. Erba)	10.00 mg
Colloidal silicon dioxide (Syloid 244 - Grace)	5.00 mg
Mint flavouring (Peppermint)	5.00 mg
Aspartame	4.00 mg
Total weight	634.00 mg

[0024] The active component and gum base are mixed with flavouring, aspartame and talc, and mixing continues for 10 minutes. The other excipients and the active component are then added, and mixing continues for a further 20 minutes, to produce a homogenous, flowable mixture.

1-c Preparation of three-layer chewing gum by compression.

[0025] The mixture of powders obtained as described in paragraphs 1-a and 1-b, and in accordance with well-known manufacturing processes, is loaded into the three loading hoppers of a rotary tablet press suitable to make three-layer tablets (e.g. Manesty Layer-Press, Liverpool, UK). In particular the mixture described in paragraph 1-a is loaded into the first and third hoppers, and the mixture described in paragraph 1-b is loaded into the second hopper. The tablet press is equipped with flat circular punches with a diameter of 13.0 mm. The machine is regulated to produce three-layer systems consisting of a first layer of 217 mg of the mixture described in paragraph 1-a, a second layer of 634 mg (containing 100 mg of acetylcysteine), and a third and final layer of 217 mg of the mixture described in paragraph 1-a. The amounts contained in the first and third layers are sufficient and necessary to produce an approx. 1.5 mm thickness of said layers. The total weight of the finished system is therefore 1068.00 mg, equivalent to a content of 100 mg of acetylcysteine. Due to the presence of the outer layers, which minimise the contact area between the gum layer and the mechanical parts of the tablet press, the compression process proceeds without difficulty, with a high output, and

## EP 1 449 525 A1

no adherence to the punches. One of the unsolved problems at the compression stage of a mixture of gum base in direct contact with mechanical parts is strong adherence, which can cause seizure of the punch-die system and can make it impossible to remove the tablets as they are produced, thus making the process impractical on an industrial scale. The tablets obtained have a smooth, shiny surface. Their organoleptic characteristics on chewing are as follows: pleasant flavour and rapid gum formation time. On chewing, the gum has an excellent consistency, even when chewed for a long time, and the chewable volume is pleasant. No after-taste.

### Reference example 1b.

**[0026]** To test the compressibility characteristics of the layer containing the active component only, tablets with a single layer containing 100 mg of acetylcysteine were prepared.

**1-bis-a** The composition described in paragraph 1-b of example 1 is used.

**1-bis-b** Preparation of single-layer chewing gum by compression.

**[0027]** The mixture of powders obtained as described above, and in accordance with well-known manufacturing processes, is loaded into the loading hopper of a rotary tablet press (e.g. Korsch, Cologne, Germany). The tablet press is equipped with flat circular punches with a diameter of 13.0 mm. The machine is regulated to produce 634 mg tablets (containing 100 mg of acetylcysteine).

**[0028]** The tablets cannot be obtained due to the difficulties encountered in the compression process. The material is compacted, but the tablet produced remains attached to one of the upper or lower punches. The production process must be interrupted immediately because the tablets cannot be removed by the automatic device of the tablet press; they can only be removed manually with a scalpel or other suitable tool, involving considerable effort. The tablet is broken during this operation, and production cannot continue. Another problem that arises is capping of the tablet, because part of the compacted material adheres to the top punch and part to the bottom punch. The result of this comparative test demonstrates the difficulty of manufacturing tablets with a gum base.

### Example 2

**[0029]** Preparation of three-layer tablets containing 100 mg of carnitine in the middle layer.

**2-a** Preparation of mixture used for the outer layers.

**[0030]** Each outer layer has the following unit composition:

Maltodextrin	200.00 mg
Talc (C. Erba)	5.00 mg
Magnesium stearate (C. Erba)	3.00 mg
Colloidal silicon dioxide (Syloid 244 - Grace)	1.00 mg
Acesulfame	3.00 mg
Orange flavouring (Givaudan)	5.00 mg
Total weight	217.00 mg

**[0031]** The following substances are mixed in a Turbula for 10 minutes: maltodextrin + silicon dioxide; the remaining components are then added, and mixing continues for a further 20 minutes. A homogenous, flowable mixture is obtained.

**2-b** Preparation of mixture constituting the middle layer.

**[0032]** The inner layer has the following unit composition:

Carnitine	100.00 mg
Gum Base (Flarer - PG Mondo TA)	500.00 mg
Talc (C. Erba)	10.00 mg
Magnesium stearate (C. Erba)	10.00 mg

## EP 1 449 525 A1

(continued)

Colloidal silicon dioxide (Syloid 244 - Grace)	5.00 mg
Orange flavouring (Givaudan)	5.00 mg
Aspartame	4.00 mg
Total weight	634.00 mg

[0033] Flavouring, aspartame and talc are added to the two gums, and mixing continues for 10 minutes. The other excipients and the active component are then added and mixing continues for a further 20 minutes, to produce a homogeneous, flowable mixture.

**2-c** Preparation of three-layer chewing gums by compression.

[0034] The mixture of powders obtained as described in paragraphs 2-a and 2-b, and in accordance with well-known manufacturing processes, is loaded into the three loading hoppers of a rotary tablet press suitable to make three-layer tablets (e.g. Manesty Layer-Press, Liverpool, UK). In particular the mixture described in paragraph 2-a is loaded into the first and third hoppers, and the mixture described in paragraph 2-b is loaded into the second hopper. The tablet press is equipped with flat circular punches with a diameter of 13.0 mm. The machine is regulated to produce three-layer systems consisting of a first layer of 217 mg of the mixture described in paragraph 2-a, a second layer of 634 mg (equivalent to 100 mg of carnitine), and a third and final layer of 217 mg of the mixture described in paragraph 2-a. The amounts contained in the first and third layers are sufficient and necessary to produce an approx. 1.5 mm thickness of said layers.

[0035] The total weight of the finished system is therefore 1068 mg, equivalent to a content of 100 mg of carnitine. The compression process proceeds without difficulty, at a high production speed, with no adherence to the punches. This test confirms that the innovative dosage form and the process allow efficient industrial production.

[0036] The tablets (chewing gum) obtained have a smooth, shiny surface. Their organoleptic characteristics on chewing are as follows: acceptable flavour, rapid gum formation, excellent consistency, no after-taste.

### Example 3

[0037] Preparation of three-layer tablets, containing 10 mg of caffeine in the middle layer.

**3-a** Preparation of mixture used for the outer layers.

[0038] Each outer layer has the unit composition described in example 1a.

**3-b** Preparation of mixture constituting the middle layer.

[0039] The inner layer has the following unit composition:

Caffeine (C. Erba)	10.00 mg
Gum Base (Flarer - PG Mondo TA)	500.00 mg
Talc (C. Erba)	10.00 mg
Magnesium stearate (C. Erba)	10.00 mg
Colloidal silicon dioxide (Syloid 244 - Grace)	5.00 mg
Mint flavouring (Peppermint)	10.00 mg
Aspartame	5.00 mg
Total weight	550.00 mg

[0040] Flavouring, aspartame and talc are added to the gum base mixed with caffeine, and mixing continues for 10 minutes. The other excipients and the active component are then added and mixing continues for a further 20 minutes, to produce a homogeneous, flowable mixture.

**3-c** Preparation of three-layer chewing gums by compression.

[0041] The mixture of powders obtained as described in paragraphs 3-a and 3-b, and in accordance with well-known

## EP 1 449 525 A1

manufacturing processes, is loaded into the three loading hoppers of a rotary tablet press suitable to make three-layer tablets (e.g. Manesty Layer-Press, Liverpool, UK). The total weight of the finished system is therefore 984.00 mg, equivalent to a content of 10 mg of caffeine.

[0042] The compression process proceeds without difficulty, at a high production speed, with no adherence to the punches. The tablets obtained have a smooth, shiny surface. Their organoleptic characteristics on chewing are as follows: acceptable flavour, very fast gum formation time, efficacious chewable volume with excellent consistency, and a slightly bitter after-taste.

### 3-d Evaluation of release of active component *in vivo*.

[0043] To establish the release of active component from the chewing gum, the tablets were tested by a panel of 3 volunteers. For each test, the volunteer was asked to chew one piece of gum for a set time. After that time the gum was ground, and the active component content analysed. The *in vivo* tests were conducted with the following chewing times: 5, 10, 15, 20, 30 and 40 minutes. The gum residue was weighed, frozen and finely ground. An exactly weighed amount of this powder was then subjected to the dissolution test according to the American Pharmacopoeia, using 1000 mL of water at 37° as dissolving fluid, and a paddle at 100 rpm. The test was performed by the spectrophotometry method, operating at 273 nm. The amount of active component released *in vivo* was determined by subtracting the amount of caffeine in the residue from the amount present in the pharmaceutical form.

[0044] Table I shows the percentages of caffeine released after various chewing times.

Table I

Chewing time	Volunteer 1	Volunteer 2	Volunteer 3	Caffeine released <i>in vivo</i> (average)	SD
5 minutes	71.52	77.02	75.07	74.54	2.79
10 minutes	86.03	83.66	84.94	84.88	1.19
15 minutes	90.18	90.97	91.07	90.74	0.49
20 minutes	89.45	91.58	89.61	90.21	1.19
30 minutes	93.92	92.25	92.49	92.89	0.90
40 minutes	92.79	93.34	92.34	92.82	0.50

[0045] As will be seen, approx. 75% of the dose of the drug is released after 5 minute chewing, and over 90% of the active component is fully released after 15 minutes. Chewing for a further 25 minutes does not lead to any significant variation in the amount of active component released by the gum. The *in vivo* results confirm that the active component contained in the pharmaceutical form is readily available for absorption. The results of the various tests are highly reproducible, as demonstrated by the low standard deviation, which confirms that the release of the drug from the medicated chewing gum is independent of the efficacy of chewing by the volunteers, and consequently guarantees wide applicability of this innovative pharmaceutical form.

### Example 4

[0046] Preparation of a set of three-layer tablets (chewing gum) containing 3 mg of benzydamine hydrochloride in the middle layer.

#### 4-a Preparation of mixture used for the outer layers.

[0047] Each outer layer has the following percentage composition:

Isomalt	85.10 %
Fructose (C. Erba)	7.66 %
Talc (C. Erba)	2.13 %
Colloidal silicon dioxide (Syloid 244 - Grace)	0.85 %
Magnesium stearate (C. Erba)	2.13 %
Mint flavouring (Givaudan Roure)	2.13 %
Total weight	100.00 %

## EP 1 449 525 A1

[0048] All the other components were added to the mixture of isomalt and colloidal silicon dioxide, and mixing continued for 20 minutes, to produce a homogeneous, flowable mixture subsequently subjected to the compression stage described below.

4-b Preparation of mixture constituting the middle layer.

[0049] The middle layer has the following unit composition:

Benzydamine hydrochloride	3.00 mg
Gum Base (Flarer - PG Mondo TA)	450.00 mg
Talc (C. Erba)	5.00 mg
Colloidal silicon dioxide (Syloid 244 - Grace)	2.00 mg
Magnesium stearate (C. Erba)	5.00 mg
Mint flavouring (Givaudan Roure)	5.00 mg
Lemon flavouring (Givaudan Roure)	10.00 mg
Aspartame	10.00 mg
Total weight	490.00 mg

[0050] All the components, previously sieved through a 25 mesh grid (equal to 710 microns), are poured into a suitable mixer, and after 20 minute stirring a homogeneous, flowable mixture is obtained which is subjected to the compression stage described in paragraph 4-c.

4-c Preparation of three-layer tablets by compression.

[0051] The mixtures of powders obtained as described in paragraphs 4-a and 4-b, and in accordance with well-known manufacturing processes, are loaded into the three loading hoppers of a rotary tablet press suitable to make three-layer tablets (e.g. Manesty Layer-Press, Liverpool, UK). The total weight of the finished system is therefore 990 mg, equivalent to a content of 3 mg of benzydamine hydrochloride. The compression process proceeds without difficulty, at a high production speed, with no adherence to the punches. The tablets obtained have a smooth, shiny surface. Their organoleptic characteristics on chewing are as follows: fast gum formation time, pleasant chewable volume with an excellent consistency, a slightly astringent flavour and no after-taste.

### Example 5

[0052] Preparation of four-layer tablets, containing 50 mg of levodopa in layer 2 and 12.5 mg of carbidopa in layer 3.

5-a Preparation of mixture for the first and fourth layers.

[0053] Each layer has the following unit composition:

Fructo-oligosaccharide	150.00 mg
Fructose (C. Erba)	10.00 mg
Talc (C. Erba)	5.00 mg
Colloidal silicon dioxide (Syloid 244 - Grace)	1.00 mg
Magnesium stearate (C. Erba)	2.00 mg
Chocolate flavouring (Givaudan Roure)	10.00 mg
Hazelnut flavouring (Givaudan Roure)	5.00 mg
Total weight	183.00 mg

[0054] All pre-sieved components are placed in a suitable container and mixed for 20 minutes. The homogeneous, flowable mixture is then subjected to the compression stage described below.

5-b Preparation of mixture constituting the middle layer.

[0055] The middle layer has the following unit composition:



## EP 1 449 525 A1

Levodopa	50.00 mg
Gum Base (Flarer - Unique 90%)	250.00 mg
Talc (C. Erba)	2.00 mg
Colloidal silicon dioxide (Syloid 244 - Grace)	0.50 mg
Magnesium stearate (C. Erba)	1.00 mg
Chocolate flavouring (Givaudan Roure)	5.00 mg
Total weight	308.50 mg

[0056] All the components, previously sifted through a 25 mesh grid (equal to 710 microns), are poured into a suitable mixer, and after 20 minute stirring a homogeneous, flowable mixture is obtained which is subjected to the compression stage described in paragraph 5-d.

**5-c** Preparation of mixture constituting the middle layer.

[0057] The middle layer has the following unit composition:

Carbidopa	12.50 mg
Gum Base (Flarer - Unique 90%)	250.00 mg
Talc (C. Erba)	2.00 mg
Colloidal silicon dioxide (Syloid 244 - Grace)	0.50 mg
Magnesium stearate (C. Erba)	1.00 mg
Chocolate flavouring (Givaudan Roure)	5.00 mg
Total weight	271.00 mg

[0058] All the components, previously sieved through a 25 mesh grid (equal to 710 microns), are poured into a suitable mixer, and after 20 minute stirring a homogeneous, flowable mixture is obtained which is subjected to the compression stage described in paragraph 5-d.

**5-d** Preparation of four-layer tablets by compression.

[0059] The mixture of powders obtained as described in paragraphs 5-a, 5-b and 5-c, and in accordance with well-known manufacturing processes, is loaded into the loading hoppers of a rotary tablet press suitable to make multi-layer tablets (e.g. Korsch). In particular, the mixture described in paragraph 5-a is loaded into the first and fourth hoppers, the mixture described in paragraph 5-b is loaded into the second hopper, and the mixture described in paragraph 5-c is loaded into the third hopper. The tablet press is equipped with convex circular punches with a diameter of 12.0 mm and regulated to produce four-layer systems consisting of a first layer of 183 mg of mixture 5-a, a second layer of 308.5 mg (equal to 50 mg of levodopa), a third layer of 271 mg (equal to 12.5 mg of carbidopa), and a fourth layer of 133 mg of the mixture described in paragraph 5-a. The amounts contained in the first and fourth layers are sufficient and necessary to produce an approx. 1.5 mm thickness of said layers. The total weight of the finished system is therefore 845 mg, equivalent to a content of 50 mg of levodopa and 12.5 mg of carbidopa. The compression process proceeds without difficulty, at a high production speed, with no adherence to the punches. The tablets obtained have a smooth, shiny surface. On chewing, the tablet presents a fast gum formation time, a pleasant chewable volume with an excellent consistency, a slightly astringent flavour and no after-taste.

[0060] The tablets were then subjected to the dissolution test according to the American Pharmacopoeia method, using 1000 mL of water at 37° as dissolving fluid and a paddle at 100 rpm. The test was performed by the spectrophotometry method, operating at 280 nm.

[0061] Table II shows the percentages of levodopa and carbidopa released by the tablets.

Table II

Time (min)	levodopa	SD of levodopa	carbidopa	SD of carbidopa
0	0.00	0.00	0.00	0.00
5	63.52	8.08	78.23	2.54

Table II (continued)

Time (min)	levodopa	SD of levodopa	carbidopa	SD of carbidopa
15	90.00	4.74	92.63	0.96
20	92.47	4.46	94.97	0.74
25	94.04	4.08	96.55	0.82
30	94.90	4.01	98.18	0.71
35	95.66	3.92	98.77	0.77
40	96.28	3.84	100.00	0.00

**Claims**

1. Tablets comprising at least one inner layer of gum base containing one or more active pharmaceutical, dietetic or nutritional ingredients and at least one outer layer comprising excipients/compression adjuvants.
2. Tablets as claimed in claim 1, comprising two outer layers which coat the inner layer of gum base.
3. Tablets as claimed in claim 1 or 2, comprising two, three or more inner layers of gum base, each of which may contain active ingredients which are the same as or different from those present in the other layers.
4. Tablets as claimed in any of claims 1-3, wherein the same or different active ingredients are also present in one or more outer layers comprising the excipients/compression adjuvants.
5. Tablets as claimed in any of claims 1-4, obtainable by direct compression of mixtures or granulates of the different components of each layer.
6. Tablets as claimed in any of claims 1-5, wherein the active ingredients are selected from analgesic, antipyretic, anaesthetic, anti-allergic, antiinflammatory, antifungal and bronchodilator drugs, antibiotics, drugs active on the cardiovascular system, decongestants, disinfectants, expectorants, mucolytics, cough suppressants, anorectics, spasmolytics, probiotics, prebiotics, enzymes and nutraceuticals.
7. Tablets as claimed in any of claims 1-6, wherein the active component content is between 0.5% and 90% on the weight of the layer in which said active component is carried, and preferably between 2 and 60%.
8. Tablets as claimed in any of claims 1-7, wherein the layers of gum base contain plasticizer selected from the group of sorbitol, xylitol, maltitol, isomalt, maltol, mannitol, maltodextrins and cyclodextrins.
9. Tablets as claimed in claim 8, wherein said plasticizer are present in the percentage of between 0.5 and 70.0% by weight.
10. Tablets as claimed in any of claims 1-9, wherein said excipients/compression adjuvants are selected from lactose, starch, modified starch, microcrystalline cellulose, sorbitol, xylitol, maltitol, isomalt, maltol, mannitol, maltodextrins, cyclodextrins, saccharose, oligosaccharose, fructose, oligofructose, dextrose, talc, colloidal silicon dioxide, magnesium stearate, starch paste, methylcellulose, ethylcellulose, polyethylene glycol, polyvinylpyrrolidone, gelatin, pectin or mixtures thereof.



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 03 00 3813

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	US 4 139 589 A (BERINGER MONIQUE; WOLTMANN SIEGFRIED) 13 February 1979 (1979-02-13) * column 1, line 27 - line 34 * * column 2, line 3 - line 30 * * column 3, line 67 - column 4, line 15 * * examples 2-5 * * figure 4 *	1-10	A61K9/24
X	WO 02 102357 A (OLSSON ROLAND ;PHARMACIA AB (SE); LINDBERG NILS-OLOF (SE); LINDELL) 27 December 2002 (2002-12-27) * page 9, line 23 - page 12, line 24 * * example 3 *	1-10	
X	WO 96 03111 A (APPLIED PHARMA RES ;REINER ALBERTO (IT); SENECA ALESSANDRO (IT)) 8 February 1996 (1996-02-08) * page 1, line 1 - line 5 * * page 2, line 24 - page 4, line 29 * * page 5, line 14 - page 11, line 8 * * claim 6 *	1,4,6,7,10	
A	DE 28 08 160 A (NORDSTROEM RABBE) 30 August 1979 (1979-08-30) * claims 1,6,9 * * page 5, paragraphs 1,2 *	1-10	A61K A23G
The present search report has been drawn up for all claims			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>8 August 2003</b>	Examiner <b>VON EGGELKRAUT, S</b>
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 03 00 3813

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

08-08-2003

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 4139589	A	13-02-1979	LU	71919 A1	06-01-1977
			CH	621063 A5	15-01-1981
			DE	2604791 A1	09-09-1976
			ES	445467 A1	16-11-1977
			FR	2302082 A1	24-09-1976
			GB	1484832 A	08-09-1977
			JP	51110016 A	29-09-1976
-----					
WO 02102357	A	27-12-2002	WO	02102357 A1	27-12-2002
-----					
WO 9603111	A	08-02-1996	IT	1274034 B	14-07-1997
			CH	689249 A5	15-01-1999
			WO	9603111 A1	08-02-1996
			EP	0769935 A1	02-05-1997
			US	5711961 A	27-01-1998
-----					
DE 2808160	A	30-08-1979	DE	2808160 A1	30-08-1979
-----					